Euclidean Capital LLC Alector, Inc. Call Options Transaction History
Euclidean Capital LLC
- $906 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALEC
# of Institutions
167Shares Held
57.8MCall Options Held
146KPut Options Held
90.8K-
Black Rock Inc. New York, NY9.1MShares$44.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.46MShares$26.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.63MShares$22.7 Million0.8% of portfolio
-
Morgan Stanley New York, NY4.36MShares$21.4 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY2.73MShares$13.4 Million0.0% of portfolio
About Alector, Inc.
- Ticker ALEC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,563,904
- Market Cap $405M
- Description
- Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...